The total number of records retrieved from this search are 38. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_887	Virus nameHerpes simplex virus	Virus strainMutant	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for Gamma 34.5	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining and hematocytometer	In-vitro virus concentration0.1 pfu/ml	In-vitro result85% cncer cell killing after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12788648
IDOV_890	Virus nameHerpes simplex virus	Virus strainMutant	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for Gamma 34.5	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining and hematocytometer	In-vitro virus concentration0.1 pfu/ml	In-vitro result95% cncer cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12788648
IDOV_893	Virus nameHerpes simplex virus	Virus strainMutant	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for Gamma 34.5	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining and hematocytometer	In-vitro virus concentration0.01 pfu/ml	In-vitro result80% cncer cell killing after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12788648
IDOV_896	Virus nameHerpes simplex virus	Virus strainMutant	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for Gamma 34.5	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining and hematocytometer	In-vitro virus concentration0.01 pfu/ml	In-vitro result80% cncer cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12788648
IDOV_1141	Virus nameHerpes simplex virus	Virus strainMutant	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for gamma 34.5, lacZ and alpha 47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01MOI	In-vitro resultNo cell killing after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID16278413
IDOV_1142	Virus nameHerpes simplex virus	Virus strainMutant	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for gamma 34.5, lacZ and alpha 47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1MOI	In-vitro resultNo cell killing after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID16278413
IDOV_1143	Virus nameHerpes simplex virus	Virus strainMutant	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for gamma 34.5, lacZ and alpha 47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01MOI	In-vitro result70% cell killing after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID16278413
IDOV_1144	Virus nameHerpes simplex virus	Virus strainMutant	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for gamma 34.5, lacZ and alpha 47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1MOI	In-vitro result70% cell killing after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID16278413
IDOV_1260	Virus nameAdenovirus	Virus strainAxdAdb-3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDouble mutated for E1A and E1B gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell lineDu145	Concentration of cell line3.0E+3 cells per well	In-vitro toxicity	AssayMTT assay	In-vitro virus concentration30 MOI	In-vitro resultSurviving cell number reached to 1000	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18063085
IDOV_2022	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line7.5E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2023	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line7.5E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 MOI	In-vitro result100% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2024	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line7.5E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 MOI	In-vitro result70% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2025	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line7.5E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 MOI	In-vitro result10% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2036	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with Docetaxel (120 nM)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line7.5E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.125 MOI	In-vitro result60% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2037	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with Docetaxel (120 nM)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line7.5E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.25 MOI	In-vitro result45% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2038	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with Docetaxel (120 nM)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line7.5E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.5 MOI	In-vitro result30% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2039	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with Docetaxel (120 nM)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line7.5E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 MOI	In-vitro result20% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2040	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with Docetaxel (120 nM)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line7.5E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration2 MOI	In-vitro result20% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2041	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationvirus in combination with Docetaxel (7.5)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line7.5E+3 cells per well	In-vitro toxicity	AssayMTS assay	In-vitro virus concentration2.15 MOI	In-vitro result70% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2042	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with Docetaxel (15 nM)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line7.5E+3 cells per well	In-vitro toxicity	AssayMTS assay	In-vitro virus concentration4.3 MOI	In-vitro result50% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2043	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with Docetaxel (30 nM)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line7.5E+3 cells per well	In-vitro toxicity	AssayMTS assay	In-vitro virus concentration8.6 MOI	In-vitro result30% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2044	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with Docetaxel (60 nM)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line7.5E+3 cells per well	In-vitro toxicity	AssayMTS assay	In-vitro virus concentration17.2 MOI	In-vitro result10% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2045	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with Docetaxel (120 nM)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line7.5E+3 cells per well	In-vitro toxicity	AssayMTS assay	In-vitro virus concentration34.4 MOI	In-vitro result10% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_3522	Virus nameAdenovirus	Virus strainAdenovirus ZD55	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion in E1B55 viral protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result95% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28880012
IDOV_3523	Virus nameAdenovirus	Virus strainAdenovirus ZD55	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion in E1B55 viral protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result75% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28880012
IDOV_3524	Virus nameAdenovirus	Virus strainAdenovirus ZD55	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion in E1B55 viral protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result60% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28880012
IDOV_3525	Virus nameAdenovirus	Virus strainAdenovirus ZD55	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion in E1B55 viral protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration20 MOI	In-vitro result50% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28880012
IDOV_3526	Virus nameAdenovirus	Virus strainAdenovirus GD55	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationGOLPH2 regulated aoncolytic adenovirus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result70% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28880012
IDOV_3527	Virus nameAdenovirus	Virus strainAdenovirus GD55	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationGOLPH2 regulated aoncolytic adenovirus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result50% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28880012
IDOV_3528	Virus nameAdenovirus	Virus strainAdenovirus GD55	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationGOLPH2 regulated aoncolytic adenovirus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result40% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28880012
IDOV_3529	Virus nameAdenovirus	Virus strainAdenovirus GD55	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationGOLPH2 regulated aoncolytic adenovirus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration20 MOI	In-vitro result20% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28880012
IDOV_3725	Virus nameVesicular stomatitis virus	Virus strainVSV-GP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationvirus expressing GP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell lineNA	In-vitro toxicityNA	AssayAbsorbance measurements	In-vitro virus concentration0.1 MOI	In-vitro result1% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryVirus induce apoptosis in cancer cell	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID29696636
IDOV_3732	Virus nameVesicular stomatitis virus	Virus strainVSV-GP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationvirus expressing GP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell lineNA	In-vitro toxicityNA	AssayAbsorbance measurements	In-vitro virus concentration10 MOI	In-vitro result3% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryVirus induce apoptosis in cancer cell	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID29696636
IDOV_3737	Virus nameVesicular stomatitis virus	Virus strainVSV-GP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationvirus expressing GP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c-rag and gamma negative xenograft for Du145 (2.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor after day 80	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID29696636
IDOV_4321	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate carcinoma	Cell lineDu145	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 pfu	In-vitro result91.4 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_5068	Virus nameAvian orthoreovirus	Virus strainARV-PB1	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro result70% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectInduction of Interferon related gene expression	Clinical trialNA	PMID28441762
IDOV_5622	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration31 pfu	In-vitro result50% of cancer cell death occurs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5842	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostae carcinoma cell line	Cell lineDu145	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayNA	In-vitro virus concentration31 pfu	In-vitro result50% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578